Other potential GPVI related targets, undergoing clinical trials and scientific investigation, have shown decreased platelet responses including aggregation, P-selectin expression and GPIIb/IIIa conformational change in response to multiple agonists, some of these targets are in use for treatment of hematological malignancies (68–70). This evidence concerns the gene ITGA2B and hematologic disorder.